Canaccord Genuity Maintains a 'Buy' on Synta Pharma (SNTA); Q1/11: G-pib Development in NSCLC Advances
Tweet
Share
E-mailGet Alerts SNTA Hot Sheet
Price: $0.34 --0%
Rating Summary:
4 Buy, 4 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
4 Buy, 4 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on Synta Pharma. (NASDAQ: SNTA), PT $8.
Canaccord analyst says, "SNTA reported Q1/11 EPS of ($0.27) and revenue of $1.1M vs. our/consensus estimates of ($0.31)/($0.28) and $1.1M/$2.1M. We estimate $40M in cash at year-end, which should be sufficient to end of 2012."
"We maintain our BUY rating on SNTA shares on the risk/reward potential of ganetespib (g-pib) for treatment of non-small cell lung cancer (NSCLC)."
For more ratings news on Synta Pharma. click here and for the rating history of Synta Pharma. click here.
Shares of Synta Pharma. closed at $5.91 yesterday.
Canaccord analyst says, "SNTA reported Q1/11 EPS of ($0.27) and revenue of $1.1M vs. our/consensus estimates of ($0.31)/($0.28) and $1.1M/$2.1M. We estimate $40M in cash at year-end, which should be sufficient to end of 2012."
"We maintain our BUY rating on SNTA shares on the risk/reward potential of ganetespib (g-pib) for treatment of non-small cell lung cancer (NSCLC)."
For more ratings news on Synta Pharma. click here and for the rating history of Synta Pharma. click here.
Shares of Synta Pharma. closed at $5.91 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- Clear Street Reiterates Buy Rating on Anterix Inc. (ATEX)
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
